Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review-Reference-Cited by-同舟云学术

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Published:2020-05-14 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Valk Sarah J¹²,Piechotta Vanessa³,Chai Khai Li⁴,Doree Carolyn⁵,Monsef Ina³,Wood Erica M⁴,Lamikanra Abigail⁶,Kimber Catherine⁵,McQuilten Zoe⁴,So-Osman Cynthia⁷⁸,Estcourt Lise J⁹,Skoetz Nicole¹⁰

Affiliation:

1. Jon J van Rood Center for Clinical Transfusion Research; Sanquin/Leiden University Medical Center; Leiden Netherlands

2. Department of Clinical Epidemiology; Leiden University Medical Center; Leiden Netherlands

3. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

4. Transfusion Research Unit, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

5. Systematic Review Initiative; NHS Blood and Transplant; Oxford UK

6. Clinical, Research and Development; NHS Blood and Transplant; Oxford UK

7. Sanquin Blood Bank; Amsterdam Netherlands

8. Erasmus Medical Centre; Rotterdam Netherlands

9. Haematology/Transfusion Medicine; NHS Blood and Transplant; Oxford UK

10. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference151 articles.

1. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea;Ahn;Journal of Korean Medical Science,2020

2. Duan K Liu B Li C Zhang H Yu T Qu J Effectiveness of convalescent plasma therapy in severe COVID-19 patients National Academy of Sciences of the United States of America 2020 10.1073/pnas.2004168117

3. Duan K Liu B Li C Zhang H Yu T Qu J The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study medRxiv 2020 101/2020.03.16.20036145

4. Pei S Yuan X Zhimin ZZ Run YR Xie Y Minxue SM Convalescent plasma to treat COVID-19: Chinese strategy and experiences medRxiv 2020 10.1101/2020.04.07.20056440

5. Shen C Wang Z Zhao F Yang Y Li J Yuan J Treatment of 5 critically ill patients with COVID-19 with convalescent plasma JAMA 2020 10.1001/jama.2020.4783

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness;Frontiers in Immunology;2024-09-09

2. The effect of convalescent plasma therapy on the rate of nucleic acid negative conversion in patients with persistent COVID-19 test positivity;Frontiers in Pharmacology;2024-08-01

3. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-06-25

4. Quality of life and cost‐effectiveness of convalescent plasma compared to standard care for hospitalized COVID‐19 patients in the CONCOR‐1 trial;Transfusion;2024-03-21

5. “A Most Equitable Drug”: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development;Journal of Law, Medicine & Ethics;2024